Prof. Laura van ‘t Veer, PhD, Agendia Chief Research Officer (CRO) and Co-founder
Prof. Laura van ’t Veer PhD is co-founder of Agendia and serves as its Chief Research Officer. As one of the world’s leading innovators in cancer diagnostics, she is widely recognized as a pioneer in the field of personalized medicine, also known as precision medicine. She has a 20-year track record in molecular oncology research, which includes more than 230 scientific publications and prestigious awards for her contributions to breast cancer care.
Dr. van ‘t Veer is best known for work stemming from a discovery she and her team made at the Netherlands Cancer Institute (NKI). They established that a specific DNA signature made up of 70 genes distinguished whether breast cancer tumors had a low or high risk of recurrence. After patenting their innovation, she and research partner René Bernards founded Agendia and launched the MammaPrint test. This translated into reducing unnecessary chemotherapy for women at low risk of metastasis, while at the same time helping identify high risk women who may benefit from therapy.
In 2010, Dr. van ‘t Veer was appointed Professor of Laboratory Medicine and Director of Applied Genomics at the University of California San Francisco. She also heads the NKI’s DNA-diagnostic laboratory. Her work has been widely acknowledged within the scientific community, earning her the Lifetime Achievement Award for Translational cancer research for the European Society of Medical Oncology. She has also received accolades from the public sector including recognition of her work on MammaPrint as one of the “five biggest health breakthroughs by women scientists” of all time. She was awarded a 2014 European Union Prize for Women Innovators that acknowledges the ways MammaPrint has helped transform breast cancer care. In 2015, the European Patent Office (EPO) recognized MammaPrint’s impact on breast cancer diagnostics by honoring Dr. van ‘t Veer with a European Inventor Award.